Market Cap 284.90M
Revenue (ttm) 332.31M
Net Income (ttm) -51.75M
EPS (ttm) N/A
PE Ratio 37.50
Forward PE N/A
Profit Margin -15.57%
Debt to Equity Ratio -0.36
Volume 4,978,000
Avg Vol 4,054,834
Day's Range N/A - N/A
Shares Out 197.85M
Stochastic %K 15%
Beta 1.04
Analysts Strong Sell
Price Target $6.75

Latest News on ESPR

Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 21 hours ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 3 months ago

Esperion Announces $210 Million Convertible Debt Financing


Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 8, 2024, 7:43 AM EST - 4 months ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?


Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13, 2024, 2:08 AM EST - 5 months ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy


Esperion Therapeutics: Strategically Positioned To Grow

Aug 16, 2024, 4:09 AM EDT - 8 months ago

Esperion Therapeutics: Strategically Positioned To Grow


Esperion to Participate in Upcoming June Investor Conferences

May 23, 2024, 9:00 AM EDT - 11 months ago

Esperion to Participate in Upcoming June Investor Conferences


Esperion Reports First Quarter 2024 Financial Results

May 7, 2024, 6:00 AM EDT - 11 months ago

Esperion Reports First Quarter 2024 Financial Results


Esperion to Participate in Upcoming May Investor Conferences

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming May Investor Conferences


Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024